NCT07627308 US vs FL-Guided Lumbar Nerve Root Injections
| NCT ID | NCT07627308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Lumbosacral Radiculopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2026-06-01 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if ultrasound-guided nerve root injections work as well as fluoroscopy (X-ray)-guided injections to treat lower back and leg pain caused by irritated nerves (lumbosacral radiculopathy) in adults aged 18 to 75 years old. The main questions it aims to answer are: * Does ultrasound guidance lower pain as effectively as fluoroscopy guidance after 3 months? * Does one method help participants recover their ability to do daily activities better than the other? * Are ultrasound-guided injections as fast and safe for participants as fluoroscopy-guided injections? Researchers will compare ultrasound-guided nerve root injections to fluoroscopy-guided nerve root injections to see if ultrasound works to treat the pain just as well while allowing participants to avoid radiation exposure. Participants will: * Receive one targeted nerve injection of medication (a steroid and numbing medicine) in their lower back using either ultrasound or fluoroscopy to guide the needle. * Stay at the clinic for 30 to 60 minutes after the procedure so researchers can check their safety. * Attend checkups at 1 week, 1 month, and 3 months to answer survey questions about their pain levels and daily functioning.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 75 years. * Clinical diagnosis of lumbar radiculopathy characterized by radicular pain, paresthesia, or weakness in a dermatomal distribution. * Magnetic Resonance Imaging (MRI)-confirmed nerve root compression due to disc herniation or foraminal stenosis. * Failure to respond to at least 3 months of conservative medical treatment. * Radiculopathy affecting the L4, L5, or combined L5-S1 levels (where the primary symptomatic level can be reliably targeted) Exclusion Criteria: * Isolated S1 radiculopathy. * Significant spinal deformities, including scoliosis \>20° or spondylolisthesis \>Grade II. * History of prior lumbar spine surgery. * Bleeding disorders (International Normalized Ratio \[INR\] \>2.5). * Severe uncontrolled diabetes mellitus (HbA1c \>8%). * Advanced cardiac, renal, or hepatic disease. * Active systemic infection or localized infection at the injection site. * Known allergies to corticosteroids or local anesthetics. * Presence of progressive neurological deficits or cauda equina syndrome. * Peripheral neuropathies mimicking radiculopathy. * Pregnancy or breastfeeding. * Severe psychiatric illness or cognitive impairment affecting study compliance.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07627308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lumbosacral Radiculopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07627308 currently recruiting?
Yes, NCT07627308 is actively recruiting participants. Contact the research team at ahmed.sami@med.tanta.edu.eg for enrollment information.
Where is the NCT07627308 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07627308 clinical trial?
NCT07627308 is sponsored by Tanta University. The trial plans to enroll 64 participants.